405
Participants
Start Date
October 31, 2015
Primary Completion Date
January 31, 2028
Study Completion Date
January 31, 2028
CM-AT
Single unit does powder of active substance (CM-AT) administered 3 times per day
Richmond Behavioral Associates, Staten Island
Montefiore Med.Cneter, Autism & Obsessive Compulsive Spectrum Program, The Bronx
Neuroscience, Inc, Herndon
University of Virginia, Dept. of Psychiatry and Neurobehavioral Sciences, Charlottesville
Carilion Clinic-Virginia Tech, Carilion School of Medicine, Roanoke
Duke Center For Autism and Brain Development, Durham
Carolina Clinical Trials, Inc., Charleston
Advent Health -Lake Mary Pediatrics, Orange City
A.P.G. Research, Orlando
Segal Institute For Clinical Research, North Miami
Cleveland Clinic Autism Center, Cleveland
Research Institute of Deaconess Clinic, Newburgh
Detroit Clinical Research Center, P.C., Bingham Farms
Lake Charles Clinical Trials, Lake Charles
L.S.U. Health Sciences Center, Shreveport
Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.), Little Rock
University of Texas, Houston-Behavioral & Biomedical Sciences, Houston
IMMUNOe Research Centers, Centennial
Focus Center of Clinical Research, Clinton
Southwest Autism Research & Resource Center (S.A.R.R.C.), Phoenix
University of Arizona, Pediatrics Multidisciplinary Research Unit, Tucson
Lovelace Scientific Resources, Albuquerque
N.R.C. Research Institute, Orange
M.I.N.D. Institute (Univ.of California, Davis), Sacramento
University of California (U.C.S.F.), San Francisco
Yale Child Study Center, New Haven
Children'S Specialized Hospital, Egg Harbor
Children's Specialized Hospital, Toms River
Clinical Research Center of Nj, Voorhees Township
Omega Medical Research, Warwick
Vanderbilt Universtiy Med.Center-Treatment&Research Inst. For Asd, Nashville
Lead Sponsor
Curemark
INDUSTRY